Comprehensive clinical evaluation of a Bevacizumab biosimilar and the originator drug for advanced non-small cell lung cancer

LIU Yanxin; LYU Xiaolin; YU Chen; LIU Anchang

doi:10.13506/j.cnki.jpr.2026.01.014

Abstract：Objective To conduct a comprehensive clinical evaluation of the bevacizumab biosimilar(Ankeda)and the originator drug(Avastin)for the treatment of advanced non-small cell lung cancer(NSCLC).Methods According to the drug instructions,evidence-based guidelines and clinical research literature,Ankeda and Avastin were evaluated across six dimensions based on real-world data.Results In terms of efficacy and safety,published studies demonstrated that Ankeda and Avastin were comparable.There were no significant differences in ORR(44.3％VS 39.2％),DCR(72.6％VS 82.1％),or the incidence of adverse reactions(45.3％VS 51.8％)between the two patient groups.Compared to Avastin,the Ankeda group showed advantages in economy,with a lower cost-effectiveness ratio(2 294.4 VS 3 125.0),a lower unit dose price(1 126 CNY VS 1 500 CNY),and a lower proportion of annual drug cost to residents' disposable income(57.80％VS 96.25％).The allocation and configuration of Ankeda was also found to be superior to that of Avastin in public medical insti-tutions.In terms of suitability,Ankeda was highly consistent with Avastin in both critical quality attributes and clinical use.Furthermore,Ankeda has achieved significant optimization and innovation in its production process,and together with Avas-tin,has promoted the widespread clinical adoption and application of bevacizumab in China.Conclusion Compared to Ava-stin,Ankeda shows no significant differences in efficacy,safety,suitability for the treatment of advanced NSCLC,while dem-onstrating significant advantages in economy and accessibility.